Fulgent Genetics Debt to Equity Ratio 2015-2024 | FLGT
Current and historical debt to equity ratio values for Fulgent Genetics (FLGT) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Fulgent Genetics debt/equity for the three months ending June 30, 2024 was 0.00.
| Fulgent Genetics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-06-30 | $0.10B | $1.13B | 0.09 |
| 2024-03-31 | $0.10B | $1.13B | 0.09 |
| 2023-12-31 | $0.10B | $1.13B | 0.09 |
| 2023-09-30 | $0.10B | $1.26B | 0.08 |
| 2023-06-30 | $0.09B | $1.26B | 0.07 |
| 2023-03-31 | $0.11B | $1.27B | 0.09 |
| 2022-12-31 | $0.12B | $1.27B | 0.09 |
| 2022-09-30 | $0.12B | $1.28B | 0.10 |
| 2022-06-30 | $0.15B | $1.31B | 0.12 |
| 2022-03-31 | $0.15B | $1.31B | 0.12 |
| 2021-12-31 | $0.11B | $1.17B | 0.10 |
| 2021-09-30 | $0.16B | $1.04B | 0.15 |
| 2021-06-30 | $0.13B | $0.92B | 0.14 |
| 2021-03-31 | $0.20B | $0.80B | 0.25 |
| 2020-12-31 | $0.13B | $0.57B | 0.23 |
| 2020-09-30 | $0.06B | $0.19B | 0.32 |
| 2020-06-30 | $0.01B | $0.09B | 0.10 |
| 2020-03-31 | $0.01B | $0.08B | 0.10 |
| 2019-12-31 | $0.01B | $0.08B | 0.07 |
| 2019-09-30 | $0.01B | $0.06B | 0.12 |
| 2019-06-30 | $0.01B | $0.05B | 0.10 |
| 2019-03-31 | $0.01B | $0.05B | 0.11 |
| 2018-12-31 | $0.00B | $0.05B | 0.05 |
| 2018-09-30 | $0.00B | $0.05B | 0.04 |
| 2018-06-30 | $0.00B | $0.05B | 0.06 |
| 2018-03-31 | $0.00B | $0.05B | 0.05 |
| 2017-12-31 | $0.00B | $0.05B | 0.06 |
| 2017-09-30 | $0.00B | $0.06B | 0.06 |
| 2017-06-30 | $0.00B | $0.06B | 0.06 |
| 2017-03-31 | $0.00B | $0.06B | 0.06 |
| 2016-12-31 | $0.00B | $0.05B | 0.07 |
| 2016-09-30 | $0.01B | $0.02B | 0.32 |
| 2016-06-30 | $0.01B | $0.02B | 0.23 |
| 2016-03-31 | $0.00B | $0.00B | 0.00 |
| 2015-12-31 | $0.00B | 0.00 | |
| 2015-09-30 | $0.00B | $0.00B | 0.00 |
| 2015-06-30 | $0.00B | $0.00B | 0.00 |
| 2014-12-31 | $0.00B | $0.00B | 0.26 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.613B | $0.289B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tempus AI (TEM) | United States | $11.978B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $6.055B | 188.82 |
| Hims & Hers Health (HIMS) | United States | $5.988B | 154.89 |
| Axonics (AXNX) | United States | $3.602B | 1762.00 |
| IRhythm Technologies (IRTC) | United States | $2.783B | 0.00 |
| Privia Health (PRVA) | United States | $2.736B | 228.00 |
| Enovis (ENOV) | United States | $2.646B | 17.94 |
| Omnicell (OMCL) | United States | $2.263B | 74.03 |
| Azenta (AZTA) | United States | $2.242B | 127.33 |
| 10x Genomics (TXG) | United States | $1.925B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.657B | 0.00 |
| Schrodinger (SDGR) | United States | $1.422B | 0.00 |
| Phreesia (PHR) | United States | $1.252B | 0.00 |
| Standard BioTools (LAB) | United States | $0.830B | 0.00 |
| Talkspace (TALK) | United States | $0.586B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.582B | 0.00 |
| Definitive Healthcare (DH) | United States | $0.508B | 88.00 |
| Health Catalyst (HCAT) | United States | $0.506B | 0.00 |
| Pulmonx (LUNG) | United States | $0.298B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.248B | 0.00 |
| TruBridge (TBRG) | United States | $0.214B | 62.22 |
| P3 Health Partners (PIII) | United States | $0.142B | 0.00 |
| American Well (AMWL) | United States | $0.139B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.106B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.064B | 0.00 |
| 111 (YI) | China | $0.057B | 0.00 |
| Zepp Health (ZEPP) | China | $0.050B | 0.00 |
| Outset Medical (OM) | United States | $0.045B | 0.00 |
| SHL Telemedicine (SHLT) | Israel | $0.042B | 0.00 |
| CareCloud (CCLD) | United States | $0.042B | 0.00 |
| Movano (MOVE) | United States | $0.028B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.023B | 0.00 |
| MSP Recovery (LIFW) | United States | $0.018B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.013B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.011B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.007B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.005B | 0.00 |
| Syra Health (SYRA) | United States | $0.004B | 0.00 |
| HeartSciences (HSCS) | United States | $0.003B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Zhongchao (ZCMD) | China | $0.002B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.000B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.000B | 0.00 |